Literature DB >> 20067552

alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.

Rong Hu1, Andrew E Aplin.   

Abstract

The serine/threonine kinase, B-RAF, is frequently mutated in melanoma and is required for cell proliferation. Proteasomal turnover of cyclins and cyclin-dependent kinase inhibitors via E3 ubiquitin ligases regulates cell cycle progression. We previously showed that B-RAF regulates Cks1, a co-factor for the F-box protein Skp2. Recently, a second F-box protein cofactor was identified, alphaB-crystallin, that binds Fbx4 and promotes cyclin D1 degradation. Here, we demonstrate that alphaB-crystallin is down-regulated in mutant B-RAF melanoma cells compared to melanocytes in a B-RAF and MEK-dependent manner. In a subset of lines, MEK inhibition was sufficient to up-regulate alphaB-crystallin protein levels; whereas in other lines combined MEK and proteasome inhibition was required. alphaB-crystallin knockdown partially stabilized cyclin D1 in melanocytes. Expression of alphaB-crystallin in mutant B-RAF melanoma cells did not promote cyclin D1 turnover under normal conditions, but did enhance turnover following etoposide-induced DNA damage. Together, these data show that alphaB-crystallin is highly expressed in melanocytes contributing, in part, to cyclin D1 turnover. Furthermore, alphaB-crystallin is down-regulated in a B-RAF-dependent manner in melanoma cells and its re-expression regulates cyclin D1 turnover after DNA damage.

Entities:  

Keywords:  B-RAF; Fbx4; cyclin D1; melanoma; αB-crystallin

Mesh:

Substances:

Year:  2010        PMID: 20067552      PMCID: PMC2855751          DOI: 10.1111/j.1755-148X.2010.00668.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  27 in total

Review 1.  The SCF ubiquitin ligase: insights into a molecular machine.

Authors:  Timothy Cardozo; Michele Pagano
Journal:  Nat Rev Mol Cell Biol       Date:  2004-09       Impact factor: 94.444

2.  Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis.

Authors:  Yang Guo; Ke Yang; Jyoti Harwalkar; Jeffrey M Nye; David R Mason; Michelle D Garrett; Masahiro Hitomi; Dennis W Stacey
Journal:  Oncogene       Date:  2005-04-14       Impact factor: 9.867

3.  Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing.

Authors:  Ivelina Mineva; Wolfgang Gartner; Peter Hauser; Alexander Kainz; Michael Löffler; Gerhard Wolf; Rainer Oberbauer; Michael Weissel; Ludwig Wagner
Journal:  Cell Stress Chaperones       Date:  2005       Impact factor: 3.667

4.  Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

Authors:  J A Diehl; F Zindy; C J Sherr
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

5.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

6.  Melanoma cell lines from different stages of progression and their biological and molecular analyses.

Authors:  K Satyamoorthy; E DeJesus; A J Linnenbach; B Kraj; D L Kornreich; S Rendle; D E Elder; M Herlyn
Journal:  Melanoma Res       Date:  1997-08       Impact factor: 3.599

7.  Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.

Authors:  Kavita V Bhatt; Laurie S Spofford; Gazelle Aram; Meghan McMullen; Kevin Pumiglia; Andrew E Aplin
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

8.  alphaB-crystallin as a marker of lymph node involvement in breast carcinoma.

Authors:  Dina Chelouche-Lev; Harriet M Kluger; Aaron J Berger; David L Rimm; Janet E Price
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

9.  Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells.

Authors:  Sean R Conner; Glynis Scott; Andrew E Aplin
Journal:  J Biol Chem       Date:  2003-06-23       Impact factor: 5.157

10.  Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts.

Authors:  M Pagano; A M Theodoras; S W Tam; G F Draetta
Journal:  Genes Dev       Date:  1994-07-15       Impact factor: 11.361

View more
  10 in total

1.  Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Authors:  Edward J Hartsough; Kevin J Basile; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2014-02-11       Impact factor: 5.852

2.  Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.

Authors:  Kaitlyn Le; Erik S Blomain; Ulrich Rodeck; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-08       Impact factor: 4.693

3.  SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

Authors:  Fred M Kaplan; Curtis H Kugel; Neda Dadpey; Yongping Shao; Ethan V Abel; Andrew E Aplin
Journal:  J Biol Chem       Date:  2012-10-17       Impact factor: 5.157

Review 4.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.

Authors:  Kevin J Basile; Kaitlyn Le; Edward J Hartsough; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2014-02-10       Impact factor: 4.693

6.  ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity.

Authors:  Y Shao; A E Aplin
Journal:  Cell Death Dis       Date:  2012-01-19       Impact factor: 8.469

7.  Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.

Authors:  Vinayak Khattar; Jaideep V Thottassery
Journal:  J Cancer Ther       Date:  2013-10-01

8.  CKS1 expression in melanocytic nevi and melanoma.

Authors:  Anna A Brożyna; Andrew Aplin; Cynthia Cohen; Grant Carlson; Andrew Joseph Page; Michael Murphy; Andrzej T Slominski; J Andrew Carlson
Journal:  Oncotarget       Date:  2017-12-23

9.  Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer.

Authors:  Lorea Valcarcel-Jimenez; Alice Macchia; Natalia Martín-Martín; Ana Rosa Cortazar; Ariane Schaub-Clerigué; Mikel Pujana-Vaquerizo; Sonia Fernández-Ruiz; Isabel Lacasa-Viscasillas; Aida Santos-Martin; Ana Loizaga-Iriarte; Miguel Unda-Urzaiz; Ivana Hermanova; Ianire Astobiza; Mariona Graupera; Julia Starkova; James Sutherland; Rosa Barrio; Ana M Aransay; Arkaitz Carracedo; Verónica Torrano
Journal:  Cell Death Dis       Date:  2018-10-11       Impact factor: 8.469

10.  CADM1 is a TWIST1-regulated suppressor of invasion and survival.

Authors:  Edward J Hartsough; Michele B Weiss; Shea A Heilman; Timothy J Purwin; Curtis H Kugel; Sheera R Rosenbaum; Dan A Erkes; Manoela Tiago; Kim HooKim; Inna Chervoneva; Andrew E Aplin
Journal:  Cell Death Dis       Date:  2019-03-25       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.